Dr. Lal PathLabs Ltd
NSE:LALPATHLAB
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2 011.05
3 605.55
|
Price Target |
|
We'll email you a reminder when the closing price reaches INR.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one LALPATHLAB stock under the Base Case scenario is 1 872.37 INR. Compared to the current market price of 3 053.65 INR, Dr. Lal PathLabs Ltd is Overvalued by 39%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Dr. Lal PathLabs Ltd
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for LALPATHLAB cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Economic Moat
Dr. Lal PathLabs Ltd
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Dr. Lal PathLabs Ltd
Balance Sheet Decomposition
Dr. Lal PathLabs Ltd
Current Assets | 13.3B |
Cash & Short-Term Investments | 11.6B |
Receivables | 911m |
Other Current Assets | 738m |
Non-Current Assets | 12.7B |
Long-Term Investments | 593m |
PP&E | 3.3B |
Intangibles | 8.3B |
Other Non-Current Assets | 561m |
Current Liabilities | 4.6B |
Accounts Payable | 2.1B |
Other Current Liabilities | 2.5B |
Non-Current Liabilities | 1.3B |
Long-Term Debt | 968m |
Other Non-Current Liabilities | 367m |
Earnings Waterfall
Dr. Lal PathLabs Ltd
Revenue
|
23.5B
INR
|
Cost of Revenue
|
-4.6B
INR
|
Gross Profit
|
18.8B
INR
|
Operating Expenses
|
-13.7B
INR
|
Operating Income
|
5.2B
INR
|
Other Expenses
|
-1.1B
INR
|
Net Income
|
4B
INR
|
Free Cash Flow Analysis
Dr. Lal PathLabs Ltd
INR | |
Free Cash Flow | INR |
In Q2 FY '25, the company reported revenues of INR 660 crores, a 9.8% increase, with profit after tax rising 18.1% to INR 131 crores. Revenue per patient improved by 5.7% to INR 844, driven by higher sample volumes. The expansion plan includes opening 15 to 20 new labs this financial year, targeting Tier 3 and 4 markets. The company's growth strategy includes increased bundled testing for chronic diseases. With ongoing investments in technology, the EBITDA margin stands at 30.7%, with an expectation to maintain or slightly exceed prior year margins. The second interim dividend announced is INR 6 per share.
What is Earnings Call?
LALPATHLAB Profitability Score
Profitability Due Diligence
Dr. Lal PathLabs Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
Score
Dr. Lal PathLabs Ltd's profitability score is 64/100. The higher the profitability score, the more profitable the company is.
LALPATHLAB Solvency Score
Solvency Due Diligence
Dr. Lal PathLabs Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Score
Dr. Lal PathLabs Ltd's solvency score is 97/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
LALPATHLAB Price Targets Summary
Dr. Lal PathLabs Ltd
According to Wall Street analysts, the average 1-year price target for LALPATHLAB is 3 220.53 INR with a low forecast of 2 424 INR and a high forecast of 3 958.5 INR.
Dividends
Current shareholder yield for LALPATHLAB is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
LALPATHLAB Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Dr. Lal PathLabs Ltd. engages in the business of running laboratories for carrying out pathological investigations. The company is headquartered in Gurgaon, Haryana and currently employs 4,110 full-time employees. The company went IPO on 2015-12-23. The firm is also engaged in running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, and other pathological and radiological investigations. The firm offers a range of tests by condition, which includes allergy, diabetes, health checkups, viral infections, fever, heart diseases, hypertension, cancer, abortions, anemia, arthritis, breast cancer, diphtheria, disorder of the liver, disorders of bone, drugs of abuse, infertility, lymphoma, tuberculosis, ovarian cancer, osteoporosis, multiple sclerosis, muscular disorder and viral infections. The Company’s subsidiaries include Paliwal Diagnostics Private Limited, Paliwal Medicare Private Limited, Dr. Lal PathLabs Nepal Private Limited, Dr. Lal PathLabs Bangladesh Pvt. Ltd. and Dr. Lal Ventures Private Limited.
Contact
IPO
Employees
Officers
The intrinsic value of one LALPATHLAB stock under the Base Case scenario is 1 872.37 INR.
Compared to the current market price of 3 053.65 INR, Dr. Lal PathLabs Ltd is Overvalued by 39%.